Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.

Bryan Chan(Royal Brisbane and Women's Hospital), Brett Hughes(Royal Brisbane and Women's Hospital)
PubMed
February 1, 2015
10.3978/j.issn.2218-6751.2014.05.01
Cited by 724

Related Papers

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
|New England Journal of Medicine|2025|277
Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)
|Annals of Oncology|2017|0